HomeCompareNLTX vs JEPQ

NLTX vs JEPQ: Dividend Comparison 2026

NLTX yields 57.31% · JEPQ yields 11.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NLTX wins by $525.6K in total portfolio value
10 years
NLTX
NLTX
● Live price
57.31%
Share price
$3.49
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$570.4K
Annual income
$128,685.50
Full NLTX calculator →
JEPQ
JPMorgan Nasdaq Equity Premium Income ETF
● Live price
11.10%
Share price
$55.52
Annual div
$6.16
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.8K
Annual income
$2,152.59
Full JEPQ calculator →

Portfolio growth — NLTX vs JEPQ

📍 NLTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNLTXJEPQ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NLTX + JEPQ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NLTX pays
JEPQ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NLTX
Annual income on $10K today (after 15% tax)
$4,871.06/yr
After 10yr DRIP, annual income (after tax)
$109,382.68/yr
JEPQ
Annual income on $10K today (after 15% tax)
$943.83/yr
After 10yr DRIP, annual income (after tax)
$1,829.70/yr
At 15% tax rate, NLTX beats the other by $107,552.97/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NLTX + JEPQ for your $10,000?

NLTX: 50%JEPQ: 50%
100% JEPQ50/50100% NLTX
Portfolio after 10yr
$307.6K
Annual income
$65,419.04/yr
Blended yield
21.27%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NLTX right now

NLTX
Analyst Ratings
5
Buy
8
Hold
1
Sell
Consensus: Hold
Altman Z
-1.6
Piotroski
3/9
JEPQ
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NLTX buys
0
JEPQ buys
0
No recent congressional trades found for NLTX or JEPQ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNLTXJEPQ
Forward yield57.31%11.10%
Annual dividend / share$2.00$6.16
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$570.4K$44.8K
Annual income after 10y$128,685.50$2,152.59
Total dividends collected$468.8K$16.3K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: NLTX vs JEPQ ($10,000, DRIP)

YearNLTX PortfolioNLTX Income/yrJEPQ PortfolioJEPQ Income/yrGap
1← crossover$16,431$5,730.66$11,930$1,110.39+$4.5KNLTX
2$26,381$8,799.86$14,133$1,224.34+$12.2KNLTX
3$41,432$13,204.52$16,632$1,340.46+$24.8KNLTX
4$63,714$19,381.50$19,454$1,457.97+$44.3KNLTX
5$96,028$27,854.89$22,626$1,576.08+$73.4KNLTX
6$141,986$39,236.06$26,175$1,694.09+$115.8KNLTX
7$206,144$54,218.66$30,133$1,811.32+$176.0KNLTX
8$294,142$73,568.04$34,531$1,927.17+$259.6KNLTX
9$412,837$98,105.15$39,403$2,041.08+$373.4KNLTX
10$570,422$128,685.50$44,787$2,152.59+$525.6KNLTX

NLTX vs JEPQ: Complete Analysis 2026

NLTXStock

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Full NLTX Calculator →

JEPQETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →
📬

Get this NLTX vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NLTX vs SCHDNLTX vs JEPINLTX vs ONLTX vs KONLTX vs MAINNLTX vs XYLDNLTX vs QYLDNLTX vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.